Life sciences partner CatSci has launched a digital tool to assess the risk of a company’s active pharmaceutical ingredient (API).
SmartPath is a digital tool created by CatSci to assess its customers’ API, project, and formulation data and offer them smart mitigation strategies. Companies using the platform will work alongside CatSci’s Director of Material Sciences to devise a plan for their API that meets budget and project needs.
CatSci’s Director of Material Sciences, Dr Robert Dennehy said: “At CatSci, we are very excited about SmartPath. In late development, it’s very common to firefight problems created through poor decisions around the API and formulation. The paradox is that we very often know the characteristics of projects that might turn into ‘problem children.’ SmartPath is a way of collating this information so it becomes directional and can be used rather than just ignored. SmartPath helps identify risks and their mitigations that are appropriate for the development phase of the drug.”
To celebrate the launch of SmartPath, CatSci is hosting a free virtual symposium on 21 June 2022 titled “A Medicine is More Than a Molecule” which will explore the crucial role that material science and solid-state properties of pharmaceutical materials play in success, as well as how SmartPath can help companies take the right steps to accomplish project objectives.